The regulation of type 1 plasminogen activator inhibitor (PAI-1) gene expression was studied in vivo employing a murine model system. Nuclease protection analysis revealed relatively high concentrations of PAT-i mRNA in the aorta, adipose tissue, heart, and lungs of untreated CB6 (BalbC X C57B16) mice. Treatment of CB6 mice with LPS, TNF-a, or transforming growth factor-,@ (TGF-ft) increased the steady-state levels of PAM-i mRNA within 3 h in all tissues examined. However, the greatest responses to TGF-ft were observed in adipose tissue and the kidney, while LPS and TNF-a strongly stimulated PAM-i gene expression in the liver, kidney, lung, and adrenals.
Introduction
Type 1 plasminogen activator inhibitor (PAI-1)' is a rapid and specific inhibitor of both tissue-(t-PA) and urokinase-(u-PA) type plasminogen activators (1) , and may be the primary regulator of plasminogen activation in vivo (2) . Deficiencies in its activity lead to accelerated fibrinolysis and bleeding (3, 4) , while abnormally high levels are frequently observed in conditions where an increased risk of thrombosis exists. For example, tenfold or greater elevations in PAI-l activity have been 1 plasminogen activator inhibitor; t-, u-PA, tissue-, urokinase-type plasminogen activator; TGF-fl, transforming growth factor-, 3. detected in the plasma of patients with gram-negative sepsis (5) , and during the second and third trimesters of pregnancy (6) . Similarly, increases in PAI-l have been documented in patients with deep vein thrombosis (7, 8) and during acute phase reactions after surgery (9, 10) , trauma (10, 1 1), and myocardial infarction (12) .
Elevations in plasma PAI-l levels may also be present in individuals with metabolic disorders associated with the development of atherosclerosis. Significant correlations have been established between PAl-1 levels and obesity (13) , noninsulindependent diabetes (14) , hyperinsulinemia (15) , and hypertriglyceridemia (15, 16) . Moreover, PAI-1 activity was shown to be increased in patients with coronary artery disease (CAD) (17) , although no such relationship could be demonstrated when hyperlipidemic or diabetic subjects were excluded from consideration (18) . These observations imply that elevations in PAI-1 activity, in association with disorders ofcarbohydrate or lipid metabolism, may contribute to the development ofatherosclerosis and CAD (19) , and may constitute a risk factor for myocardial infarction (16, 20) .
The mechanisms underlying these alterations in plasma PAI-1 activity are largely unknown. In vitro, PAI-I is synthesized and secreted by a variety of cell types, including cultured endothelial cells of arterial, venous, and microvascular origin, as well as smooth muscle cells, kidney mesothelial and tubular epithelial cells, lung fibroblasts, hepatocytes, and several transformed cell lines (for review, see reference 2). Its synthesis in cells is positively regulated by many agents. These include: LPS, the toxic principle of gram-negative bacteria; the inflammatory cytokines interleukin 1 and TNF-a; growth factors such as transforming growth factor-# (TGF-,B), basic fibroblast growth factor, and epidermal growth factor; and hormones, such as glucocorticoids and insulin. Many of (cpm) . The peak area defined by the 445-nt PAI-l mRNA protection fragment (see Fig. 1 ) typically contained 60-80% ofthe total radioactivity per lane when analyzed by (3-scanning.
To normalize for variability in sample loading, aliquots of protection assay samples were slot-blotted and hybridized to a 32P-labeled rat 18s rDNA probe as described (27) . Relative values for l8s RNA content were obtained for each sample by densitometric scanning of slotblot autoradiograms. To provide normalization factors for the estimation of PAI-I mRNA content (see below), the 18s values for each sample were divided by the mean 18s relative value for each experiment.
To determine the absolute amount of PAI-I mRNA in each sample, a 96-nt synthetic PAI-I RNA standard was synthesized by in vitro transcription and purified by preparative electrophoresis on a 6% polyacrylamide sequencing gel. Identical amounts (1.2 pg) ofthis standard were added to each hybridization reaction to generate an 80-nt protected fragment corresponding to 1.0 pg PAI-I RNA in each lane. 
Results
To examine expression of the PAI-l gene in vivo, total RNA was extracted from tissues ofadult male CB6 mice and the level of PAI-I mRNA determined by ribonuclease protection assay (see Methods). Results from a representative animal are shown in Fig. 1 kidney, and thymus. Low levels were present in liver, spleen, gut, brain, and testes. To assess for variation in RNA loading, the 1 8s ribosomal RNA levels ofeach sample were determined separately by slot-blot hybridization (see Methods), and are shown in Fig. 1 B.
To determine the average concentration of PAI-l mRNA in the various tissues, multiple animals were analyzed as in Fig.  1 . The amount of PAI-1 mRNA in total RNA samples from each tissue was then determined by direct comparison to a synthetic RNA standard (see Methods), and its concentration expressed as pg/,hg total RNA (Table I) . While some variation was noted between animals, a pattern of gene expression consistent with that depicted in Fig. 1 was revealed. The aorta contained the highest concentration of PAI-l mRNA (2.018 pg/,g total RNA), followed by adipose tissue (0.606 pg/Mug), heart (0.583 pg/Mug), and lung (0.351 pg/Mg). Considerably lower concentrations were detected in the liver (0.021 pg/Mug), kidney (0.091 pg/Mug), and other tissues.
The average yield of total RNA was determined for each tissue and employed to calculate its specific PAI-l mRNA content (i.e., the total amount ofPAI-I mRNA within the tissue as a whole). The highest amounts of PAI-I mRNA were present in the liver and kidney, due to the greater total RNA content of these organs (Table I) . Relatively high amounts of PAI-l mRNA were also present in the heart and lung, which contained much lower yields of total RNA, but higher concentrations ofPAI-I mRNA. Intermediate amounts ofPAI-I mRNA were present in adipose tissue. However, this latter estimate reflects only the PAI-I mRNA content of epididymal fat, and thus excludes the potential contribution of other murine fat deposits (e.g., retroperitoneal or subcutaneous).
Treatment with LPS has previously been shown to increase plasma PAI-l activity in rabbits (5) and rats (28) , as well as in human volunteers (29) . To assess the effect of LPS on murine PAI-l gene expression, mice were injected intraperitoneally with 50 ,g LPS (2.0 mg/kg) or with saline vehicle. Tissues were removed 3 h later, and total RNA was prepared and analyzed for PAI-I mRNA as above. The results are presented in Fig. 2 , with the optimal autoradiographic exposure time shown for each tissue (see legend to Fig. 2 ). Increases in PAI-l mRNA were detected in all 13 tissues examined, although the extent of induction varied considerably. Quantitative analysis of data from two replicate experiments was performed employing a ,3-scanning device (Table II) . The greatest fold induction occurred in the liver (305-fold), followed by the kidney (93-fold), lung (74-fold), and adrenals (28-fold). Increases of 10-fold or less were observed in all other tissues.
To evaluate the time course of this response, mice were injected with 50 Mg LPS and selected tissues (liver, kidney, heart, and lung) were removed at 1, 3, 8, and 24-h intervals. The PAI-1 mRNA concentrations for these tissues were then determined as above. For each tissue, a detectable increase was observed within 1 h (Fig. 3) . Maximal induction was apparent by 3 h in the kidney, heart, and lung, and decreased to 40-60% of maximal levels by 8 h. In contrast, the liver appeared to respond to LPS more slowly, and did not reach the maximal level until 8 h. The levels of PAI-I mRNA remained significantly elevated in each tissue at 24 h after treatment. The dose dependency ofthe response to LPS was then examined. CB6 mice were injected with doses of LPS ranging from 0.005-50 ug (0.2 gg-2.0 mg/kg), and the liver, kidney, heart, and lung were removed 3 h later for analysis. Although PAI-I mRNA increased in each tissue in a dose-dependent manner (Fig. 4 A) , significant differences in sensitivity were evident. For example, at the minimal dose tested (5.0 ng LPS), a 24-fold increase was observed in the liver, while lesser responses were observed in the kidney (3.7-fold increase) and lung (2.6-fold increase). PAI-I mRNA levels in the heart did not increase at this dose. In fact, the heart displayed only a modest increase (1.5-2.1-fold), even when doses of 50-500 ng were employed. At the highest dose tested (50 ,ug), the concentration of PAI-l mRNA in the heart, kidney, and liver rose to 2.5-4.0 pg/sg total RNA. In contrast, the concentration of PAI-I mRNA in the lung rose to 33.5 pg/,ug at this dose, nearly 10-fold higher than in the other tissues.
C3H/HeJ mice exhibit greatly decreased sensitivity to the toxic effects of LPS. This behavior appears to result from a defect in LPS signal transduction in these animals (30) . To assess the role of this signal transduction pathway in the response of PAI-I mRNA to LPS, C3H/HeJ mice were injected with increasing amounts of LPS (0.005-50 Mg). The mice were killed at 3 h postinjection and the concentration of PAI-l mRNA in liver, kidney, heart, and lung was determined as above. In most instances, little change was evident in PAI-I mRNA levels at doses below 500 ng LPS (Fig. 4 B) , a dose that resulted in pronounced increases in these tissues in CB6 mice (Fig. 4 A) . Even at the highest doses employed, relatively minimal increases in PAI-I mRNA were observed in C3H/HeJ mice (Fig. 4 B) .
These results indicate that the signaling deficit in C3H/HeJ mice attenuates the response ofthe PAI-I gene to LPS. Because the LPS-mediated release of TNF-a is a primary event in the induction of septic shock (31) , and this response is attenuated in C3H/HeJ mice (30), we evaluated the response ofthe PAI-I gene to TNF-a itself. Recombinant human TNF-a (0.16 mg/ kg) was administered to either CB6 or C3H/HeJ mice by intraperitoneal injection, and the tissues were removed 3 h later for analysis. A response qualitatively similar to that of LPS was observed in CB6 mice (Fig. 5 A; compare to Fig. 2 ). (Note variation in autoradiographic exposure times in Fig. 2 .) The highest concentrations of PAI-i mRNA after treatment with TNF-a were detected in the lung. In addition, strong responses were observed in the liver and kidney (Fig. 5) and adrenals (not shown). Nearly identical responses were evident in C3H/HeJ mice (Fig. 5 B) , indicating that the signaling defect in these animals does not extend to TNF-a. The fold induction of PAI-1 mRNA in response to TNF-a was determined by (i-scanning and is compared with that of LPS in Table IT. TGF-j3, a multifunctional polypeptide present in platelets (32) , is also present in monocytes, and is released from monocytes in response to LPS (33) . TGF-,3 stimulates PAM-gene expression in a variety ofcultured cell types (2), and experimental infusion of TGF-,3 was recently shown to increase plasma PAI-I activity in rabbits (34) . To examine the effect of TGF-,i on murine PAI-I gene expression, CB6 mice were injected intravenously with recombinant human TGF-ft (0.12 mg/kg) or with saline vehicle. The mice were killed 3 h later and their tissues removed for analysis. As shown in Fig. 6 , TGF-13 administration increased the level ofPAI-I mRNA in all tissues examined. However, in contrast to LPS and TNF-a, the strongest responses to TGF-j3 were observed in adipose tissue and kidney, while considerably less induction of PAI-I mRNA was observed in the liver and lung. (Note the use ofa shorter autoradiographic exposure time for adipose tissue in Fig. 6 .) Similar results were obtained in C3H/HeJ mice (data not shown), indicating that the effects ofTGF-13 were not due to contamination by LPS. The fold induction of PAI-I mRNA by TGF-,B was determined by densitometric scanning and is compared with that of LPS and TNF-a in Table TI murine tissues (Fig. 1) revealed PAI-I mRNA to be present in all tissues examined. However, its concentration varied by over 100-fold (Table I) . Relatively high concentrations were detected in aorta, heart, lung, and adipose tissue, while lower concentrations were found in kidney, liver, and many other tissues. More limited studies on the tissue distribution ofPAI-I mRNA have been performed in rats (35) and humans (36) . In rats, PAI-1 mRNA was detected predominantly in the lung. Lower levels were observed in the heart, while PAI-l mRNA was undetectable in skeletal muscle, liver, and kidney. In human tissues, PAI-l mRNA was relatively abundant in myocardium. However, in contrast to murine liver (Table I) or rat liver (35), high message levels were also detected in human liver. This discrepancy may reflect interspecies differences, or possible abnormalities (e.g., acute phase reactions) in the surgical specimens of human liver employed for analysis.
To assess the potential contribution of murine tissues to plasma PAI-I synthesis, their total PAI-I mRNA content was calculated (Table I) . While the liver contained very low concentrations ofPAI-I mRNA (0.021 pg/sg total RNA), it exhibited the highest PAI-l mRNA content (184 pg), because of its greater yield of total RNA relative to other tissues. However, murine kidney, heart, and lung also contained significant amounts ofPAI-I mRNA (94-106 pg). The PAI-I mRNA content of other tissues (e.g., aorta, adipose tissue, or skeletal muscle) could not be estimated in full, because, these tissues were not extracted in their entirety. Nonetheless, the apparently high biosynthetic capacity ofnonhepatic tissues for PAI-I (Table I) and the widespread expression of PAI-I mRNA in murine tissues (Fig. 1) suggests that plasma PAI-l may originate from multiple tissues in vivo.
The highest concentrations of murine PAI-l mRNA (> 2 pg/ag) were detected in the aorta, consistent with observations that PAI-I is a major biosynthetic product of cultured bovine aortic endothelial cells (37) and smooth muscle cells (38) . Newly synthesized PAI-I is deposited into the extracellular matrix of these and other cell types (39) (40) (41) , where it may protect matrix components from proteolysis by limiting plasmin generation. These observations suggest that PAI-I may be deposited in vivo within the aortic subendothelium or media, where it may function to preserve the integrity ofconnective tissue elements, including fibrillar collagen (42) . However, the presence of PAI-I within aortic tissues has yet to be demonstrated, and the identity of the cell types expressing PAI-I mRNA remains to be established. Interestingly, PAI-I mRNA was recently localized by in situ hybridization to mesenchymal-appearing cells within human atherosclerotic plaques (43). The synthesis of PAI-I by these cells has been postulated to contribute to the development of atherosclerosis (19) .
Obesity is an independent risk factor for the development of atherosclerosis and cardiovascular disease (44) , and is associated with related metabolic disorders such as hypertriglyceridemia (45), hyperinsulinemia, and noninsulin-dependent diabetes (46) . In obese humans, elevations in plasma PAI-l levels appear to correlate with insulin (13, 15) . Insulin has been reported to stimulate PAI-l production by cultured human hepatocytes (47) , suggesting that increased hepatic synthesis of PAI-l may account for its elevation in obese subjects. However, analysis oftotal RNA prepared from murine tissues ( Fig.  1) revealed that high concentrations of PAI-1 mRNA are present in the epididymal fat pad, a large mass of adipose tissue present in the abdominal cavity. In the animals employed for this study, the PAI-l mRNA content of epididymal fat was approximately one-fifth that of the liver (Table I) . In obese animals, the mass of this tissue typically increases severalfold, in which case its biosynthetic capacity for PAI-l would be ex- pected to rival that of the liver. These observations raise the possibility that elevations in plasma PAI-I levels associated with obesity may result from the constitutive synthesis of PAI-1 in adipose tissue. Plasma PAI-I levels can be dramatically increased in patients with gram-negative sepsis and disseminated intravascular coagulation (5) . As a model of gram-negative sepsis, LPS was administered to mice by intraperitoneal injection. As shown in Fig. 2 , LPS treatment resulted in the increased accumulation of PAI-I mRNA in each of 13 tissues examined. The extent of this response varied considerably between tissues. In particular, LPS treatment led to a profound stimulation of PAI-I mRNA in the liver, kidney, lung, and adrenals. Ofthese tissues, the greatest induction of PAI-I mRNA (> 300-fold) was observed in the liver, which also exhibited enhanced sensitivity to the effects of LPS (Fig. 4) . These results may reflect the rapid uptake of LPS by hepatic cells, and its increased concentration in the liver relative to other tissues (48, 49) . However, kinetic analysis revealed the liver responded more slowly to LPS than other tissues, exhibiting maximal levels of PAI-I mRNA at -8 h after LPS treatment, while maximal responses were evident at 3 h in the kidney, heart, and lung (Fig. 3) . Because previous investigations have shown that plasma PAI-I activity consistently reaches a maximum at 4 h after LPS challenge in rats (35), rabbits (5) , and man (50), the data shown in Fig. 3 suggest that the synthesis of PAI-I in nonhepatic tissues may be the primary determinant of circulating PAI-I levels in sepsis. However, because of its high biosynthetic capacity for PAI-1, the liver may also contribute substantially to changes in the plasma PAI-I pool.
Many ofthe toxic effects ofLPS have been attributed to the actions of TNF-a, which is released by cells of monocytic lineage in response to LPS (31) . TNF-a suppresses the fibrinolytic activity ofendothelial cells by modulating PAI-I and t-PA production (51, 52) , and has been shown to increase plasma PAI-I levels in rats (52) and human cancer patients (53). Here we report that injection of TNF-a into mice markedly stimulates the accumulation of PAI-1 mRNA, with a tissue-specific response pattern qualitatively similar to that of LPS. Relatively strong increases are elicited by both agents in the liver, kidney, lung, and adrenals (Table TI) . Moreover, the peak response of PAI-I mRNA to LPS (3 h in most tissues) follows the peak of TNF-a activity in plasma, which occurs 1 h after LPS injection (54) . In C3H/HeJ mice, which exhibit an attenuated response of TNF-a to LPS, the response of PAI-I mRNA was similarly attenuated (Fig. 4 B) , while a robust response to TNFa was observed (Fig. 5 B) . These results suggest that the effects of LPS on murine PAI-I gene expression are indirect, and are mediated by TNF-a. However, in cultured endothelial cells, LPS has been shown to directly increase PAI-l mRNA levels independent of de novo protein synthesis (27) . We therefore cannot exclude the possibility that the LPS signaling deficit in C3H/HeJ mice also attenuates direct effects of LPS on PAI-I gene expression in vivo.
TGF-fl, which has been implicated in numerous biological processes involving tissue remodeling and wound repair (32) , may also mediate the response of PAI-I mRNA to LPS. In vitro studies have shown that TGF-# stimulates PAI-I biosynthesis in a wide variety of cell types, including endothelial cells (27) , smooth muscle cells (55) , fibroblasts (56) , epithelial cells (57) , and several transformed cell lines, including hepatoma cells (58) . In vivo, TGF-,3 is present in platelets (32), peripheral blood monocytes, and tissue macrophages (33) , and is released upon activation of these cells. Because experimental infusion of TGF-fB has been demonstrated to increase plasma PAT-i activity in rabbits (34), we investigated the response ofthe murine PAI-I gene to TGF-,B. Injection of purified, recombinant human TGF-# stimulated the accumulation of PAI-I mRNA in numerous tissues. Strong induction was observed in adipose tissue and kidney (Fig. 6) , while a relatively modest induction was apparent in the liver and lung. In contrast, LPS and TNF-a elicited strong responses in these tissues (Figs. 2 and 5 ). These results indicate that TGF-,3 exerts selective effects on PAI-I gene expression distinct from those of LPS or TNF-a, and is therefore unlikely to mediate the response of PAI-I to LPS in tissues such as the liver and lung. However, the responsiveness of the PAI-I gene to TGF-3 in a wide variety of cultured cell types, as opposed to the relatively limited specificity ofLPS and TNF-a (2), suggests that TGF-,B may promote PAI-I synthesis in additional cell types in vivo.
In previous studies, we have shown that LPS, TNF-a, and TGF-,B directly increase the steady-state level of PAI-I mRNA in cultured endothelial cells by stimulating PAI-I gene transcription (27) . In this report, we have extended these observations to show that each ofthese agents increases PAI-I mRNA levels in a broad spectrum of murine tissues, consistent with its increased expression in vascular cells. The action of these agents may lead to local or systemic alterations in fibrinolytic activity during gram-negative sepsis, inflammation, and thrombosis, and contribute to pathophysiologic fibrin deposition and extracellular matrix accumulation in association with these processes. Elucidation of the mechanisms regulating expression of the PAI-I gene in vivo will enable further investigation of its role in vascular disease.
